Chinese Biotech Firm Ascletis Leads Series E Round In American Pharma 3-V Biosciences

Login to View

An affiliate of Hong Kong-listed Chinese biotech company Ascletis Pharma has led a US$18 million series E financing round in San Francisco-based clinical-stage pharmaceutical firm 3-V Biosciences, said Ascletis in a statement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 3 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription for $359

Enjoy comprehensive and exclusive data you can't find elsewhere!

Subscribe for $359

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in